Aclaris Therapeutics Inc. (NASDAQ:ACRS) shares traded down 5.7% during trading on Monday . The company traded as low as $19.61 and last traded at $19.72, with a volume of 57,745 shares traded. The stock had previously closed at $20.91.

A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 24th. Guggenheim assumed coverage on shares of Aclaris Therapeutics in a research report on Friday, June 10th. They set a “buy” rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $28.50.

The company’s market cap is $400.63 million. The stock’s 50 day moving average is $19.74 and its 200-day moving average is $19.35.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Wednesday, May 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.15. Equities analysts predict that Aclaris Therapeutics Inc. will post ($2.45) EPS for the current fiscal year.

An institutional investor recently bought a new position in Aclaris Therapeutics stock. Turner Investments L.P. purchased a new stake in Aclaris Therapeutics Inc. (NASDAQ:ACRS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 57,694 shares of the company’s stock, valued at approximately $1,554,000. Turner Investments L.P. owned approximately 0.29% of Aclaris Therapeutics at the end of the most recent quarter.

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.